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Background: Identification of the culprit genes underlying multifactorial diseases is one of the most important
current challenges of molecular genetics. While recent advances in genomics research have accelerated the
discovery of susceptibility genes, much remains to be learned about the functions of disease-associated genetic
variants. Recently, Moore and co-workers identified, in the donor genome, an association between a common
genetic variant (rs4730751) in the gene encoding caveolin-1 (CAV1), a major structural component of caveolae,
and long-term allograft survival.
Methods: Four hundred seventy-five renal recipients consecutively transplanted were included in this study. Donor
genomic DNA was extracted and used to genotype CAV1 rs4730751 Single Nucleotide Polymorphism.
Results: Patients receiving a graft carrying CAV1 rs4730751 AA genotype displayed a significant decrease in
estimated glomerular filtration rate and a significant increase in serum creatinine in both univariate and multivariate
analyzes. Moreover, patients receiving a graft with CAV1 AA genotype significantly developed more interstitial
fibrosis lesions on systematic biopsies performed 3 months post-transplantation.
Conclusions: Genotyping of CAV1 may be relevant to identify patients at risk of adverse renal transplant outcome.Background
Most common diseases are complex and result from
multiple genetic and environmental factors. The recent
advances in genotyping and sequencing technologies
have revolutionized our understanding of the genetics of
complex traits. For instance, more than 2,600 associated
common risk alleles have been identified, with convincing
associations in about 350 different complex traits [1].
Nevertheless for the vast majority of associated alleles, the
identities of causal genes and variants, as well as their
function, remain unclear.
Fibrosis refers to the excessive and persistent forma-
tion of scar tissue, which is responsible for morbidity
and mortality associated with organ failure in a variety
of chronic diseases [2]. Renal fibrosis is a central feature
of all progressive renal diseases that ultimately leads to* Correspondence: francois.glowacki@chru-lille.fr
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article, unless otherwise stated.end-stage renal failure. In particular, kidney fibrosis is es-
pecially common in renal allografts and is a major cause
of allograft dysfunction and loss [3]. This fibrotic process
results from numerous injuries related to immune allo-
graft rejection or non immune-mediated chronic damages
including calcineurin inhibitor toxicity. Broadly speaking,
renal fibrosis is characterized by an excessive wound-
healing process of the kidney tissue after chronic, sus-
tained injury resulting in an excessive accumulation of
extracellular matrix components. Despite intensive stud-
ies, the underlying cause or genetic factors involved in the
pathogenesis of renal fibrosis are still largely unknown. Re-
cently, Moore and co-workers identified, in the donor gen-
ome, an association between a common genetic variant
rs4730751 in the gene encoding caveolin-1 (CAV1), a
major structural component of caveolae, and long-term
allograft survival. More precisely, grafts carrying AA geno-
type are associated with a higher graft loss frequency
(38.6% for AA genotypes vs 22.3% and 22.2% for AC and
CC genotypes, respectively, at 12 years post-transplant) [4].
Nevertheless, the impact of CAV1 polymorphism on renal
allograft function, or graft histology, is currently unknown.ed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Demographic and clinical characteristics
according to CAV1 genotype (rs4730751)








BMI (kg/m2) 23.4 ± 4.0 24.4 ± 4.6 24.1 ± 4.3
Age at transplantation (years) 44.0 ± 14.4 47.8 ± 12.5 47.5 ± 12.3
Sex of the recipient (M/F) 69.4%/30.6% 66.0%/34.0% 60.0%/40.0%
Age of donor (years) 41.9 ± 15.8 45.8 ± 14.9 45.4 ± 15.1
Sex of the donor (M/F) 68.6%/31.4% 70.3%/29.7% 69.0%/31.0%
Initial nephropathy
Glomerulonephritis 31.4% 33.3% 32.1%




Hereditary nephropathy 17.1% 15.9% 21.0%
Other 8.6% 8.2% 5.6%




Cold ischemia time (h) 20.8 ± 6.9 21.3 ± 6.9 20.8 ± 6.7
HLA mismatch (A/B/DR) 3.6 ± 1.4 3.4 ± 1.9 3.4 ± 1.3
Delayed graft function 12.9% 25.7% 20.3%
Acute rejection 8.6% 15.6% 9.8%
NODAT 17.3% 15.7% 20.6%
CMV disease 5.6% 10.8% 9.8%
Proteinuria (year 2) 10% 17.3% 19.4%




ATG induction 58.6% 55.6% 51.8%
Immunosuppressive
therapy (year 1)
Steroids therapy (%) 40 36 42
Mycophenolate daily
dose (g/day)
1.23 ± 0.26 1.40 ± 0.51 1.31 ± 0.60
Tacrolimus daily dose
(mg/kg/day)
0.08 ± 0.03 0.08 ± 0.04 0.09 ± 0.04
Tacrolimus trough blood
level (ng/mL)
7.36 ± 3.40 8.40 ± 3.29 7.69 ± 3.30
NODAT: new onset diabetes after transplantation, BMI: body mass index, HLA:
human leukocyte antigen, ATG: antithymoglobulin.
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of specialized plasma membrane microdomains called
caveolae, is a crucial regulator of tissue fibrosis. Caveolae
are involved in numerous biological functions ranging
from endocytosis and transcytosis to signal transduction
[5,6]. In the kidney, CAV1 is expressed in mesangial
cells, epithelial cells, Bowman’s parietal epithelial cells,
as well as in renal proximal tubular epithelial cells [7].
As expected from their function and tissue distribution,
caveolae and CAV1 are implicated in a variety of human
disorders, including cancer and cardiovascular and in-
flammatory diseases [6,8,9]. In particular, caveolae have
a well-described profibrotic role in the context of trans-
forming growth factor beta (TGFβ) signaling. Whereas
TGFβ receptor endocytosis via clathrin-coated pit-
dependent internalization promotes TGFβ signaling, the
lipid raft-caveolar internalization pathway facilitates the
degradation of TGFβ receptors, therefore decreasing
TGFβ signaling [10-12]. In line with this, CAV1 null
mice exhibit an extensive interstitial fibrosis following
unilateral ureteral obstruction, a disease model of TGFβ-
driven renal fibrogenesis [13].
The aim of this study was to evaluate, in an independ-
ent large cohort of transplant recipients receiving a
tacrolimus-based immunosuppressive protocol, the im-
pact of donor CAV1 rs4730751 genetic variant on renal
transplant function, graft histology, and graft survival.
Results
Description of the cohort
In this retrospective survey, the mean follow-up was 4.8
± 2.6 years after renal transplantation. CAV1 rs4730751
AA, AC, and CC genotypes were observed in respect-
ively 7.6% (n = 36), 40.8% (n = 194), and 51.6% (n = 245)
of patients. Alleles A and C frequencies (respectively
0.28 and 0.72) are in equilibrium with the Hardy Wein-
berg law. Demographic and clinical parameters were not
significantly different between AA, AC, or CC genotype
groups (Table 1).
Association between rs4730751 and renal graft function
Renal function and proteinuria were evaluated according
to CAV1 genotype. By univariate analysis, in the per
protocol population, patients receiving a graft carrying
CAV1 rs4730751 AA genotype displayed a significant de-
crease in estimated glomerular filtration rate (eGFR),
whereas eGFR remained stable for patients transplanted
with a rs4730751 AC or CC graft (Figure 1). More pre-
cisely, eGFR modification between 2 and 5 years post-
transplant was −10 ± 9 mL/min/1.73 m2 for AA group,
0 ± 11 mL/min/1.73 m2 for AC group, and 1 ± 13 mL/
min/1.73 m2 for CC group (AA vs AC, P = 0.003; AA vs
CC, P = 0.003) (Figure 2). Two years after transplant-
ation, CAV1 genotype did not influence recipients’proteinuria. However, 5 years after transplantation,
35.7% of patients with a CAV1 AA genotype graft devel-
oped proteinuria vs 21.3% for AC and 14.3% of patients
with CC genotype (P < 0.05) (Table 1). In multivariate ana-
lysis of the renal transplant function determinants, analysis
of covariance for serum creatinine levels (expressed as
log10-transformed, Table 2) showed a significant interaction
Figure 1 Evolution of the estimated glomerular filtration rate according to donor CAV1 genotype (rs4730751) between 2 and 5 years
post-transplant. Estimated glomerular filtration rate was evaluated according to aMDRD. Data are described as mean ± standard deviation.
*P < 0.05 vs 2 years **P < 0.005 vs 2 years.
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between genotype and delayed graft function (DGF) (P =
0.003). In the group of patients that did not experience
DGF, 3-month creatinine levels were similar for all CAV1
graft genotypes (P = 0.10). By contrast, for patients with a
past history of DGF (22.1%), 3-month creatinine levels were
significantly different (AA vs AC: P = 0.01; AA vs CC: P =
0.001; AC vs CC: P = 0.07). Due to the significant inter-
action between genotype and time post-transplant, the
change in creatinine slopes over time differed significantly
according to genotype. Specifically, creatinine increased sig-
nificantly over time only for genotype AA (P = 0.0005). Of
note, the slope for genotype AC nearly reached significanceFigure 2 Estimated glomerular filtration rate modification according to do
Estimated glomerular filtration rate was evaluated according to aMDRD.(P = 0.08). The donor age (P < 0.0001) was also an inde-
pendent predictor of creatinine increase over time (P <
0.0001).
Analysis of covariance for eGFR levels (expressed as
log10-transformed) was consistent with the conclusions
regarding serum creatinine levels (Table 2). Again, signifi-
cant interactions were observed between genotype and
time (P = 0.02) as well as between genotype and delayed
graft function (P = 0.001). Three-month eGFR levels were
not significantly different for patients that did not experi-
ence delayed graft function (P = 0.24), whereas 3-month
eGFR levels were statistically different according to graft
genotype for patients that experienced delayed graftnor CAV1 genotype (rs4730751) between 2 and 5 years post-transplant.
Table 2 Covariance analysis of repeated measures for creatinine and estimated glomerular filtration rate
Serum creatinine eGFR (aMDRD)
Variable Beta F P Beta F P
Intercept 0.9319 1.8358




Time (per year) 0.0262 17.63 <0.0001 −0.0298 18.23 <0.0001




Delayed graft function 0.08 0.78 0.53 0.47
No Reference Reference
Yes −0.0956 0.1322




Donor age (per year) 0.0036 84.10 <0.0001 −0.0045 140.76 <0.0001
Acute rejection NS 15.15 0.0001
No Reference
Yes −0.0695
DGF: delayed graft function, eGFR: estimated glomerular filtration rate, aMDRD: abbreviated modification of diet in renal diseases, NS: not significant.
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CC: P = 0.02). In particular, eGFR decreased significantly
over time for patients transplanted with a AA graft geno-
type (P = 0.0005) or a AC graft genotype (P = 0.04). This
decrease was faster for AA genotype compared to AC
genotype (test of equality of slopes: P = 0.01). Other pre-
dictors associated with an eGFR decrease were a higher
donor age (P < 0.0001) and an acute rejection after trans-
plantation (P = 0.0001).
By Kaplan-Meier analysis, rs4730751 did not affect
renal survival (Figure 3).
Association between rs4730751 and renal graft histology
Regardless of the biopsy indications (systematic or on
clinical indication), neither the development of tacroli-
mus nephrotoxicity nor acute tubular necrosis were in-
fluenced by CAV1 genotype (Table 3). Similarly, the
frequency of acute rejection lesions was independent of
CAV1 genotype (data not shown). Concerning the clinic-
ally indicated biopsies, the incidence of interstitial fi-
brotic lesions (ci = 1 and ci = 2) was statistically higher
for grafts carrying the rs4730751 AA genotype compared
to AC or CC grafts. By contrast, on systematic biopsies,
no significant association was found between genotypesand interstitial fibrosis score. Furthermore, as the num-
ber of patients exhibiting severe interstitial fibrotic le-
sions was too low (ci = 3: 6 patients), statistical analysis
could not be performed in this subgroup.
Discussion
Since the first draft of the human genome has been re-
leased, substantial progress has been made in our under-
standing of the genetic basis of many complex diseases. In
particular, large-scale analyses have provided important
new insights into the genetic architecture of chronic kidney
disease by identifying new susceptibility loci [14,15]. Never-
theless, much less is known about the allelic spectrum for
genes underlying kidney fibrosis [16], a progressive patho-
genic process ultimately leading to end-stage renal failure.
Recently, using a tagging approach, Moore et al. identified
and validated an association between a common genetic
variant (rs4730751) within the CAV1 gene and renal allo-
graft failure and fibrosis, when present in the donor kidney
[4]. Furthermore, CAV1, the primary structural component
of plasma membrane caveolae, has independently been
identified as a crucial inhibitor of tissue fibrosis and has
been functionally implicated in the pathogenesis of various
fibrotic disorders including kidney fibrosis [17].
Figure 3 Association between donor CAV1 rs4730751 Single Nucleotide
Polymorphism genotype and death-censored allograft failure.
Table 3 Impact of CAV1 genotype on graft histological lesion
Biopsies CAV1 genot
AA
Systematic n = 10
Acute tubular necrosis 0
Tacrolimus acute tubular toxicity 1 (10.0%)
Tacrolimus chronic vascular toxicity 1 (10.0%)
Acute rejection (cellular or humoral) 0
IF/TA grade I or II 5 (50.0%)
IF/TA grade III 0
Clinically indicated biopsies n = 7
Acute tubular necrosis 2 (28.6%)
Tacrolimus acute tubular toxicity 1 (14.3%)
Tacrolimus chronic vascular toxicity 2 (28.6%)
Acute rejection (cellular or humoral) 1 (14.3%)
IF/TA grade I or II 5 (71.4%)*
IF/TA grade III 0
Total of biopsies n = 17
Acute tubular necrosis 2 (11.8%)
Tacrolimus acute tubular toxicity 3 (17.6%)
Tacrolimus chronic vascular toxicity 3 (17.6%)
Acute rejection (cellular or humoral) 1 (5.9%)
IF/TA grade I or II 10 (58.8%)**
IF/TA grade III 0
BK virus nephropathy 2 (11.8%)
*P < 0.05. **P < 0.01.
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the CAV1 rs4730751 AA genotype are at higher risk of
chronic allograft dysfunction. Our results showed that pa-
tients receiving a graft with CAV1 AA genotype signifi-
cantly developed more interstitial fibrosis lesions (ci = 1
and ci = 2) and are more prone to experience kidney dam-
ages (evaluated by both proteinuria and decrease of glom-
erular filtration rate) over time. Modification of graft
function was observed with both creatinine measurement
and estimation of the glomerular filtration rate (using ab-
breviated modification of diet in renal diseases (aMDRD)
formula), suggesting that graft function modification was
independent of biases potentially associated to aMDRD
formula. Moreover, for patients with a past history of
graft-delayed function, CAV1 genotype is a determinant of
renal function recovery at 3 months post-transplant. How-
ever, no association with tacrolimus-induced lesions of
acute or chronic toxicity was found, suggesting that this
genotype does not influence tacrolimus nephrotoxicity.
Other risk factors associated with worse renal allograft
function were donor age and a past history of acute rejec-
tion. These risk factors are usually observed in renals
ype
AC CC
n = 43 n = 69
0 1 (1.4%)
7 (16.3%) 18 (26.1%)
5 (11.6%) 7 (10.1%)
1 (2.3%) 7 (10.1%)
14 (32.6%) 18 (26.1%)
1 (2.3%) 1 (1.4%)
n = 38 n = 49
12 (31.6%) 11 (22.4%)
5 (13.2%) 9 (18.4%)
7 (18.4%) 9 (18.4%)
9 (23.7%) 11 (22.4%)
11 (28.9%)* 5 (10.2%)*
1 (2.6%) 3 (6.1%)
n = 81 n = 118
12 (14.8%) 12 (10.2%)
12 (14.8%) 27 (22.9%)
12 (14.8%) 16 (13.5%)
10 (12.3%) 11 (9.3%)
25 (30.8%)** 23 (19.5%)**
3 (3.7%) 3 (2.5%)
3 (3.7%) 4 (3.4%)
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hort was not sufficient to observe an association between
graft survival and CAV1 genotype and thus we were un-
able to independently replicate findings obtained by
Moore et al. [4]. Of note, patients receiving a graft with
AA genotype associated with the worse outcome were
transplanted with younger grafts and experienced de-
layed graft function to a lesser extent. While non-
significant, these observations strengthen the potential
impact of donor CAV1 genotype on renal outcome. As
donor/recipient mixed chimerism may contribute to
kidney fibrosis [19], it cannot be excluded that recipient
CAV1 genetic polymorphism may influence graft out-
come. Nevertheless, Moore et al. failed to find an asso-
ciation between recipient CAV1 rs4730751 and allograft
outcome in a large cohort [4].
Although our study, as well as that of Moore et al.,
identified a statistical association between the rs4730751
tag Single Nucleotide Polymorphism (SNP) and renal
allograft function, the precise variants that have a causal
role remain to be identified [4]. As the rs4730751 tag
SNP is not in linkage disequilibrium with other genetic
variants located in exons that may truncate or otherwise
alter CAV1 gene product, the causative variant is likely
to be regulatory rather than coding. Indeed, for multifac-
torial traits, most of the genetic variants identified so far
have been mapped to non-protein-coding regions, where
they influence transcriptional output [20]. Interestingly,
Manetti et al. recently identified an association between
the CAV1 rs959173 intronic SNP and systemic sclerosis,
a connective tissue disease associated with fibrosis [21].
Therefore, CAV1 genetics is likely to be complex, and
deep resequencing at the CAV1 locus is required to
clearly define the causal variants.
Conclusions
As renal transplantation is suggested as an in vivo model
of accelerated tissue fibrosis, genotyping of CAV1 may
be relevant in other renal and non-renal diseases charac-
terized by tissue fibrosis. In line with this, Chand et al.
recently found an association between rs4730751 CAV1
genetic polymorphism and the prognosis of ANCA asso-
ciated vasculitis, with a protective effect of the CC geno-
type [22]. Also, CAV1 genotyping may extend to other
chronic kidney disease conditions in which CAV1 is
thought to play a major role.
Methods
Ethics statement
The protocol has been certified to be in accordance with
French laws by the Institutional Review Board of Centre
Hospitalier Regional Universitaire de Lille. French health
authorities have waived the requirement for consent re-
lated to donors who are no longer alive. DNA collectionwas registered at French ‘Ministère de l’Enseignement
Supérieur et de la Recherche’ under the number DC-
2008-642. Genotyping analysis and immunosuppressive
therapy were performed as described in our local regular
protocol of renal transplant care.
Patients
Four hundred seventy-five French renal recipients con-
secutively transplanted between 1999 and 2005 partici-
pated in this cohort survey. Only recipients of kidney
from deceased donor were eligible for inclusion. Patients
under 18 years and combined graft recipients were also
excluded from this study.
Immunosuppressive therapy
All patients received initially biological induction (antithy-
moglobulin (ATG) or anti-CD25 monoclonal antibodies),
tacrolimus, Mycophenolate Mofetil (initially 1 g twice
daily, thereafter tapered), and steroids (500 mg at day 0,
250 mg at day 1, and next 20 mg/day until day 7). Steroids
were stopped at day 8 for patients without immunological
risk or delayed graft function. The initial daily dose of ta-
crolimus (PROGRAF®) was 0.075 mg/kg twice a day
(0.15 mg/kg/day). Then, the dose was adjusted to reach a
trough blood concentration between 10 and 15 ng/mL the
first 3 months, and between 8 and 12 ng/mL within the
first year. After 1 year, trough blood levels were targeted
between 6 and 8 ng/mL. Nevertheless, the daily tacrolimus
dose was adjusted according to the clinical state of the
patient.
Genotyping
Deceased donor DNA was extracted from lymphocytes
used for the pre-transplantation cross match test as part
of routine practice.
Each amplification reaction was carried out in a total
volume of 25 μL 10 mMTris-HCl buffer pH 8.4 contain-
ing 50 mM KCl, 0.2 mM of each dNTP, 2 μM MgCl2,
0.4 μM of each primer (CAV1F: TGGTATCTAACATAC
AGCC and CAV1R: GGAGGTATGGCATGTGGA),
200 ng DNA, and 0.6 U Taq DNA polymerase (Life
Technologies, Carlsbad, CA, USA). After an initial de-
naturation step at 94°C for 3 min, 35 cycles of 1 min at
94°C, 1 min of hybridization at 60°C, and 1 min of ex-
tension at 72°C were carried out. A final extension
period of 7 min was performed at 72°C. Size and specifi-
city of PCR fragments were controlled on 1% agarose
gels after incorporation of an intercalator (EvaGreen,
Jena Bioscience, Jena, Germany).
After purification with the ExoSap-IT enzyme (USB)
(Affymetrix, Santa Clara, CA, USA), amplicon nucleotide
sequences were determined using an automated DNA se-
quencer (ABI Prism® 3130 Genetic Analyser, Life Tech-
nologies, Carlsbad, CA, USA). Fragments were amplified
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BigDye® Terminator v3.1 kit (Life Technologies, Carlsbad,
CA, USA) and analyzed with SeqScape v2.5.6 software
(Life Technologies, Carlsbad, CA, USA).
Allograft outcome
During the follow-up period, clinical parameters were
recorded, including DGF (defined by the requirement of
dialysis session(s) during the first week after transplant-
ation) and the renal function (estimation of the eGFR,
according to aMDRD formula [23]. Proteinuria was only
recorded at 2 years and 5 years post-transplant and was
categorized as followed: no proteinuria (less than
300 mg/24 h or less than 300 mg/g creatinine) or overt
proteinuria.
Histopathology
Retrospectively, histological data were available for the
last 207 patients included in this cohort (216 biopsies).
One hundred twenty-two biopsies were systematically
performed 3 months after transplant, whereas the
remaining 94 biopsies were carried out on clinical indi-
cation (median time post transplantation: 110 days (88
to 470 days)). Borderline changes were not considered
for acute rejection. Pathological criteria for the diagnosis
of tacrolimus toxicity were cytoplasmic isometric vacuo-
lization of tubular cells (acute tubular toxicity) and/or
arteriolar nodular hyalinosis (chronic arteriolar hyalino-
sis). The semi-quantitative analysis of graft interstitial fi-
brosis (ci score) was graded according to the updated
Banff 07 classification [24].
Statistical analysis
To assess the homogeneity of the patient population,
genotype frequencies were tested against Hardy-Weinberg
equilibrium using a chi-square test.
Categorical variables are described as absolute numbers
and proportions, continuous variables as mean ± standard
deviation or median [25th to 75th percentiles]. Baseline
characteristics according to genotype were compared with
Chi-square tests for categorical variables and with analyses
of variance for continuous variables.
Serum creatinine data and eGFR data from 3 months to
6 years (2,934 measurements) were analyzed using
repeated-measures analysis of covariance (PROC MIXED,
SAS Institute, Cary, NC, USA), with time, genotype and
their interaction as independent predictors, and adjusted
for baseline characteristics. Data were log10-transformed
due to skewed distributions. The repeated-measures co-
variance structure was specified as a spatial power func-
tion to handle unequally spaced measurements over time.
When either creatinine or eGFR change was not linear
with respect to a continuous predictor, the predictor was
transformed into a binary variable, the cut-off value beingthe value minimizing the Bayesian Information Criterion
of the model. Parameters of the model were tested with
polynomial contrasts. Regression underlying assumptions
were visually inspected with residual plots. Statistical sig-
nificance was set at α = 0.05.
Graft survival related to CAV1 genotype was estimated
by the Kaplan-Meier method and compared with the
logrank test.
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